Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Adamis Pharmaceuticals : Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (Form 8-K)

09/13/2021 | 04:42pm EDT
Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Resignation of Directors

On September 7, 2021, Roshawn A. Blunt, a director of the Company and a member of the Audit Committee, Compensation Committee and Nominating and Governance Committee, notified the Company that for personal reasons, effective as of October 1, 2021, she was resigning as a director of the Company. Her resignation was not because of any disagreement with the Company or the board of directors on any matter relating to the Company's operations, policies, practices or financial statements.

Financial Statements and Exhibits.

(d) Exhibits.

None.

2

Disclaimer

Adamis Pharmaceuticals Corporation published this content on 13 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 September 2021 20:41:05 UTC.


© Publicnow 2021
All news about ADAMIS PHARMACEUTICALS CORPORATION
10/18ADAMIS PHARMACEUTICALS : New High-Dose Naloxone Product for the Treatment of Opioid Overdo..
PU
10/18ADAMIS PHARMACEUTICALS CORP : Other Events (form 8-K)
AQ
10/18Health Care Stocks Sputtering in Late Trade
MT
10/18Health Care Stocks Weighing on Broader Monday Markets
MT
10/18Adamis Pharma Shares Rise 16% After FDA Approves Zimhi for Opioid Overdose
DJ
10/18ADAMIS PHARMACEUTICALS : Gets FDA Approval For Opioid Overdose Injection; Shares Surge
MT
10/18Wall Street Set for Positive Open as Earnings-Heavy Week Kicks Off; China GDP Growth Sl..
MT
10/18Top Premarket Gainers
MT
10/18ADAMIS PHARMACEUTICALS : Receives FDA Approval for ZIMHI
AQ
10/18Adamis Pharmaceuticals Corporation Receives FDA Approval for ZIMHI
CI
More news
Financials (USD)
Sales 2021 22,0 M - -
Net income 2021 -24,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,35x
Yield 2021 -
Capitalization 161 M 161 M -
Capi. / Sales 2021 7,31x
Capi. / Sales 2022 16,1x
Nbr of Employees 130
Free-Float 98,6%
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 1,08 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Dennis J. Carlo President, Chief Executive Officer & Director
David C. Benedicto Chief Financial & Accounting Officer
Richard C. Williams Chairman
Ronald B. Moss Chief Medical Officer
Karen K. Daniels Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ADAMIS PHARMACEUTICALS CORPORATION122.63%167
JOHNSON & JOHNSON4.07%431 385
ROCHE HOLDING AG15.84%337 562
NOVO NORDISK A/S57.04%239 813
PFIZER, INC.14.34%235 986
ELI LILLY AND COMPANY44.35%219 674